Who we are

Welcome to Aptamist

At Aptamist we specialize in the development of cutting-edge aptamers for a wide range of applications including therapeutics, diagnostics, sensors or basic research.

Our mission

We are committed to advancing the field of aptamer technology and deliver innovative solutions that can revolutionize healthcare, agriculture and food quality.

Our story

Aptamist was born out of a desire to push the boundaries for molecular recognition and support local researchers and industry with aptamer services and expertises. Today, Aptamist collacorates with and supports customers and partners in DK, EU and US.

What we do

With a focus on the intended application, we offer tailormade aptamer development, support for R&D projects and a continuosly expanding library of predeveloped aptamers.

OUR TEAM

At Aptamist, our team is headed by CEO Daniel Dupont, PhD, an expert with over 20 years of experience in the field of aptamers contributing to more than 30 peer-reviewed research publications.
Our team is composed of professionals with deep expertise in nucleic acid and protein biochemistry, biophysics and extensive experience with in vitro and in vivo applications.
Together, we bring a comprehensive understanding of aptamer development, ensuring innovative and reliable solutions, tailored to your specific needs.

Selection of documented aptamer experience

Peer-reviewed articles

  • Selection of locally administered ocular tissue-targeting RNA aptamers using in vivo SELEX (DOI: 10.3390/biom15020255)
  • Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels (DOI: 10.3390/biom15020255)
  • Targeting ocular tissues with intravenously administered aptamers selected by in vivo SELEX (DOI: 10.1016/j.omtn.2024.102352)
  • Unbiased plasma profiling using pre-selected RNA aptamer pools predicts mortality in COVID-19 and identifies protein risk factors (DOI: 10.1016/j.omtn.2024.102253)
  • A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model (DOI: 10.1016/j.ymthe.2024.05.002)
  • Differential RNA aptamer affinity profiling on plasma as a potential diagnostic tool for bladder cancer (DOI: 10.1093/narcan/zcac025)
  • A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry (DOI: 10.1073/pnas.2112942118)
  • Multivalent Aptamer-Functionalized Single-Strand RNA Origami as Effective, Target-Specific Anticoagulants with Corresponding Reversal Agents (DOI: 10.1002/adhm.202001826)
  • An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications (DOI: 10.1016/j.omtn.2017.10.004)
  • A Conjugate of Two tPA-Binding RNA Aptamers Efficiently Inhibits Fibrinolysis (DOI: 10.1089/nat.2016.0637)
  • An RNA Aptamer Inhibits a Mutation-Induced Inactivating Misfolding of a Serpin (DOI: 10.1016/j.chembiol.2016.04.013)
  • Expected and unexpected features of protein-binding RNA aptamers (DOI: 10.1002/wrna.1360)
  • Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules (DOI: 10.1021/acs.bioconjchem.6b00007)
  • Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools (DOI: 10.1093/nar/gkv700)
  • Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation (DOI: 10.1160/TH14-08-0686)
  • Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites (DOI: 10.1371/journal.pone.0119207)
  • Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry (DOI: 10.1021/cb400619v)
  • Methods To Identify Aptamers against Cell Surface Biomarkers (https://doi.org/10.3390/ph4091216)
  • Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism (DOI: 10.1158/1541-7786.MCR-12-0349)
  • Nucleic acid aptamers against proteases (DOI: 10.2174/092986711797189556 or FREE version)
  • Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding (DOI: 10.1261/rna.2338210)
  • RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1 (DOI: 10.1021/bi100066j)

TALK TO US

Have any questions? You are always welcome to contact us for an informal discussion about aptamers.

GET IN TOUCH